The combination of lenalidomide and dexamethasone (Len–Dex) is a commonly used initial therapy for newly diagnosed multiple myeloma (MM). Although the initial response rates and toxicity are ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 3 study titled A RANDOMIZED, 2-ARM, ...

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is conducting a Phase 3 ...

Patients with untreated symptomatic MM were randomly assigned at a one-to-one-to-one ratio to lenalidomide plus low-dose dexamethasone until disease progression (Rd continuous), Rd for 72 weeks (18 ...

The addition of lenalidomide to R-CHOP chemotherapy improved survival outcomes among patients with newly diagnosed diffuse large B-cell lymphoma, according to study results published in Journal of ...

Lenalidomide was combined with pulsed dexamethasone (40 mg/day, days 1–4 and 15–18) after two cycles in five patients, and from the start in three patients (Table 1, patient nos. 9–16).

There was no difference in risk for lenalidomide plus cyclophosphamide, lenalidomide plus dexamethasone, and melphalan alone. "These data suggest that the future role of oral melphalan in ...

Researchers sought to determine whether salvage high-dose chemotherapy plus ASCT would be effective for patients with relapsed/refractory MM.

Following is a transcript of his remarks: One of the most important questions in myeloma these days is how long you should continue maintenance for. I mean, I'm gonna say five studies and a meta ...

Sanofi’s Sarclisa (isatuximab) has been approved by the European Commission (EC) to treat newly diagnosed multiple myeloma ...

Lenalidomide offers an exciting advance in the treatment of the 5q– MDS patient. It has the ability to alter the course of MDS by inducing hematologic and cytogenetic responses, resulting in ...

This segment discusses how maintenance therapy should be tailored based on different patient risk profiles and examines current evidence supporting lenalidomide alone vs combination maintenance ...